为何淀粉样蛋白仍是阿尔茨海默病临床试验的靶点。 - Suppr

Suppr

超能文献

Why Amyloid Is Still a Target for Alzheimer Disease Clinical Trials.

作者信息

McDade Eric

机构信息

Department of Neurology, Washington University School of Medicine, St Louis, Missouri.

出版信息

J Am Geriatr Soc. 2019 Apr;67(4):845-847. doi: 10.1111/jgs.15829. Epub 2019 Mar 9.

DOI:10.1111/jgs.15829

PMID:30851119

Abstract

摘要

相似文献

Why Amyloid Is Still a Target for Alzheimer Disease Clinical Trials.

J Am Geriatr Soc. 2019 Apr;67(4):845-847. doi: 10.1111/jgs.15829. Epub 2019 Mar 9.

Major Clinical Trials Failed the Amyloid Hypothesis of Alzheimer's Disease.

J Am Geriatr Soc. 2019 Apr;67(4):841-844. doi: 10.1111/jgs.15830. Epub 2019 Mar 9.

Antibody drugs for Alzheimer's show glimmers of promise.

Nature. 2015 Jul 30;523(7562):509-10. doi: 10.1038/nature.2015.18031.

Editorial: An Industry Perspective: Future of Anti-Amyloid Trials.

J Prev Alzheimers Dis. 2020;7(3):142-143. doi: 10.14283/jpad.2020.26.

Why are drug trials in Alzheimer's disease failing?

Lancet. 2010 Oct 30;376(9751):1466. doi: 10.1016/S0140-6736(10)61994-0.

Commentary: The EU/US Task Force's Future for Anti-Amyloid Trials: Faites Vos Jeux.

J Prev Alzheimers Dis. 2020;7(3):199-200. doi: 10.14283/jpad.2020.29.

Alzheimer's drugs take a new tack.

Nature. 2012 Sep 6;489(7414):13-4. doi: 10.1038/489013a.

Alzheimer antibody drugs show questionable potential.

Nat Rev Drug Discov. 2015 Sep;14(9):591-2. doi: 10.1038/nrd4709.

The search for Alzheimer disease therapeutics - same targets, better trials?

Nat Rev Neurol. 2020 Nov;16(11):597-598. doi: 10.1038/s41582-020-00414-3.

[Neurotoxicity of amyloid beta proteins].

Nihon Yakurigaku Zasshi. 2008 May;131(5):326-32. doi: 10.1254/fpj.131.326.

引用本文的文献

Discoveries and future significance of research into amyloid-beta/α7-containing nicotinic acetylcholine receptor (nAChR) interactions.

Pharmacol Res. 2023 May;191:106743. doi: 10.1016/j.phrs.2023.106743. Epub 2023 Apr 20.

Design, synthesis and biological evaluation of light-driven on-off multitarget AChE and MAO-B inhibitors.

RSC Med Chem. 2022 Jun 1;13(7):873-883. doi: 10.1039/d2md00042c. eCollection 2022 Jul 20.

A Novel Compound YS-5-23 Exhibits Neuroprotective Effect by Reducing β-Site Amyloid Precursor Protein Cleaving Enzyme 1's Expression and HO-Induced Cytotoxicity in SH-SY5Y Cells.

Neurochem Res. 2020 Sep;45(9):2113-2127. doi: 10.1007/s11064-020-03073-4. Epub 2020 Jun 18.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Why Amyloid Is Still a Target for Alzheimer Disease Clinical Trials.

J Am Geriatr Soc. 2019 Apr;67(4):845-847. doi: 10.1111/jgs.15829. Epub 2019 Mar 9.

Major Clinical Trials Failed the Amyloid Hypothesis of Alzheimer's Disease.

J Am Geriatr Soc. 2019 Apr;67(4):841-844. doi: 10.1111/jgs.15830. Epub 2019 Mar 9.

Antibody drugs for Alzheimer's show glimmers of promise.

Nature. 2015 Jul 30;523(7562):509-10. doi: 10.1038/nature.2015.18031.

Editorial: An Industry Perspective: Future of Anti-Amyloid Trials.

J Prev Alzheimers Dis. 2020;7(3):142-143. doi: 10.14283/jpad.2020.26.

Why are drug trials in Alzheimer's disease failing?

Lancet. 2010 Oct 30;376(9751):1466. doi: 10.1016/S0140-6736(10)61994-0.

Commentary: The EU/US Task Force's Future for Anti-Amyloid Trials: Faites Vos Jeux.

J Prev Alzheimers Dis. 2020;7(3):199-200. doi: 10.14283/jpad.2020.29.

Alzheimer's drugs take a new tack.

Nature. 2012 Sep 6;489(7414):13-4. doi: 10.1038/489013a.

Alzheimer antibody drugs show questionable potential.

Nat Rev Drug Discov. 2015 Sep;14(9):591-2. doi: 10.1038/nrd4709.

The search for Alzheimer disease therapeutics - same targets, better trials?

Nat Rev Neurol. 2020 Nov;16(11):597-598. doi: 10.1038/s41582-020-00414-3.

[Neurotoxicity of amyloid beta proteins].

Nihon Yakurigaku Zasshi. 2008 May;131(5):326-32. doi: 10.1254/fpj.131.326.

引用本文的文献

Discoveries and future significance of research into amyloid-beta/α7-containing nicotinic acetylcholine receptor (nAChR) interactions.

Pharmacol Res. 2023 May;191:106743. doi: 10.1016/j.phrs.2023.106743. Epub 2023 Apr 20.

Design, synthesis and biological evaluation of light-driven on-off multitarget AChE and MAO-B inhibitors.

RSC Med Chem. 2022 Jun 1;13(7):873-883. doi: 10.1039/d2md00042c. eCollection 2022 Jul 20.

A Novel Compound YS-5-23 Exhibits Neuroprotective Effect by Reducing β-Site Amyloid Precursor Protein Cleaving Enzyme 1's Expression and HO-Induced Cytotoxicity in SH-SY5Y Cells.

Neurochem Res. 2020 Sep;45(9):2113-2127. doi: 10.1007/s11064-020-03073-4. Epub 2020 Jun 18.